Pioneering study on activated platelets in thrombus and embolus formation among stroke patients joint study between Yokohama and Morioka

Pioneering study on activated platelets in thrombus and embolus formation among stroke patients joint study between Yokohama and Morioka - PATHFINDER

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022911

Enrollment

100

Registered

2016-06-27

Start date

2016-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral embolism due to non-valvular atrial fibrillation (NVAF)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) age more than 50 years old 2) patients with NVAF who are not taking anti platelets and/or oral anti coagulants 3) Davigatran-naive patients with NVAF

Exclusion criteria

Exclusion criteria: 1) current internal bleeding, history of increased bleeding risk, or planned procedure with risk of uncontrolled bleeding 2) patients with renal disfunction (CrCl <30mL/min) 3) patients with clinical risk of hemorrhage (including hemorrhagic stroke within 6 months) 4) patients with indwelling spinal or epidural catheterization or patients at least 1 hur after the procedure 5) patients taking itraconazole

Design outcomes

Primary

Measure	Time frame
activity of anti PAR-1 antibody and platelet aggregation before, 4 weeks, and 8 weeks after administration of Dabigatran (Prazaxa R)	—

Countries

Japan

Contacts

Public ContactYasuo Terayama

Iwate Medical University Division of Neurology and Gerontology, Department of Internal Medicine

teray@iwate-med.ac.jp019-651-5111

Outcome results